Mainz Biomed (NASDAQ: MYNZ) 10% holder reports 643,850 shares owned
Rhea-AI Filing Summary
Mainz Biomed N.V. disclosed an insider ownership position through a Form 3 filing. Donahue Kevin Michael, identified as a 10% owner of the company, reported beneficial ownership of 643,850 shares of common stock, held directly. The event date for this ownership report is 10/17/2025. This filing serves as an initial statement of his existing holdings rather than detailing a new stock transaction.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Donahue Kevin Michael
Role
10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 643,850 shares (Direct)
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the Mainz Biomed (MYNZ) Form 3 filing disclose?
The Form 3 filing discloses that 10% owner Donahue Kevin Michael beneficially owns 643,850 shares of Mainz Biomed N.V. common stock, held directly.
What is the event date for this Mainz Biomed (MYNZ) insider ownership report?
The date of the event requiring the Form 3 statement is listed as 10/17/2025.
Is this Mainz Biomed (MYNZ) Form 3 reporting a trade or just holdings?
This Form 3 functions as an initial statement of beneficial ownership, listing that 643,850 common shares are owned directly, rather than describing a specific stock trade.
What is the insider’s relationship to Mainz Biomed (MYNZ)?
In the insider data, Donahue Kevin Michael is identified as a 10% owner of Mainz Biomed N.V..